Frequently Asked Questions
The market is segmented based on , By Type (Bochdalek Hernia, Morgagni Hernia Diaphragm), Treatment (Extracorporeal Membrane Oxygenation, Others), Diagnosis (Prenatal, Postnatal), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Congenital Diaphragmatic Hernia Drugs Market size was valued at USD 4.00 USD Billion in 2022.
The Global Congenital Diaphragmatic Hernia Drugs Market is projected to grow at a CAGR of 7% during the forecast period of 2023 to 2030.
The major players operating in the market include Pfizer, Mylan, Fresenius Kabi, Hikma Pharmaceuticals, Novartis, Teva Pharmaceutical Industries, Johnson & Johnson Services, Integra LifeSciences, B. Braun SE, C.R. Bard, Cook, W. L. Gore & Associates, Dipromed Srl.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
